Please login to the form below

Not currently logged in
Email:
Password:

Abivax

This page shows the latest Abivax news and features for those working in and with pharma, biotech and healthcare.

Trial data suggest Abivax’ drug may clear latent HIV

Trial data suggest Abivax’ drug may clear latent HIV

The drug reduced HIV DNA in cells over 28 days. French biotech Abivax has new data for its HIV drug candidate ABX464 that suggest it may suppress latent HIV in reservoirs – ... Those anti-inflammatory properties have encouraged Abivax to carry out a

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics